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Abstract
Ras proteins are crucial players in differentiation and oncogenesis and constitute important drug targets. The localization
and activity of Ras proteins are highly dependent on posttranslational modifications at their C-termini. In addition to an
isoprenylated cysteine, H-Ras, but not other Ras proteins, possesses two cysteine residues (C181 and C184) in the C-terminal
hypervariable domain that act as palmitoylation sites in cells. Cyclopentenone prostaglandins (cyPG) are reactive lipidic
mediators that covalently bind to H-Ras and activate H-Ras dependent pathways. Dienone cyPG, such as 15-deoxy-D12,14-
PGJ2 (15d-PGJ2) and D
12-PGJ2 selectively bind to the H-Ras hypervariable domain. Here we show that these cyPG bind
simultaneously C181 and C184 of H-Ras, thus potentially altering the conformational tendencies of the hypervariable
domain. Based on these results, we have explored the capacity of several bifunctional cysteine reactive small molecules to
bind to the hypervariable domain of H-Ras proteins. Interestingly, phenylarsine oxide (PAO), a widely used tyrosine
phosphatase inhibitor, and dibromobimane, a cross-linking agent used for cysteine mapping, effectively bind H-Ras
hypervariable domain. The interaction of PAO with H-Ras takes place in vitro and in cells and blocks modification of H-Ras
by 15d-PGJ2. Moreover, PAO treatment selectively alters H-Ras membrane partition and the pattern of H-Ras activation in
cells, from the plasma membrane to endomembranes. These results identify H-Ras as a novel target for PAO. More
importantly, these observations reveal that small molecules or reactive intermediates interacting with spatially vicinal
cysteines induce intramolecular cross-linking of H-Ras C-terminus potentially contributing to the modulation of Ras-
dependent pathways.
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Introduction
Ras proteins are key regulators of cellular proliferation, survival
or senescence. In addition to their role in cellular physiology, Ras
proteins are involved in many pathophysiological processes. In
fact, mutations in the Ras genes are found in 30% of human
cancers [1]. Therefore, since their discovery, Ras oncogenes have
been the subject of intense research. The three Ras genes, H-, N-,
and K-Ras display extensive homology but also important
distinctive features (reviewed in [2,3]).
Ras proteins are GTP-binding proteins which hydrolyze GTP
with the concourse of GTPase activating proteins. Ras activity is
controlled by a cycle between the GTP-bound active state and the
GDP-bound inactive state. In the GTP-bound state, Ras proteins
may interact with effectors including Raf, PI3K and RalGDS,
among others [3,4], to activate various signaling pathways with
impact on cell cycle regulation, cytoskeleton organization,
transcriptional regulation or membrane trafficking. Ras activity
is subjected to a complex modulation at many different levels. Ras
activation, requiring the exchange of bound GDP for GTP, can
occur by interaction with GTP exchange factors (GEFs), which in
turn may transduce signals from growth factor receptors or sense
levels of intracellular mediators, including calcium and diacylgly-
cerol. In addition, GDP-GTP exchange can be favoured by the
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direct action of reactive oxygen or nitrogen species, such as nitric
oxide, on Ras proteins [5].
Posttranslational modifications of Ras proteins play a key role in
their localization and activity. All Ras proteins are isoprenylated at
a cysteine residue present in the CAAX box located at the C-
termini [6]. In addition, whereas H-Ras is palmitoylated at two
cysteine residues present in the hypervariable domain (C181 and
C184), N-Ras contains a single palmitoylation site (C181) and K-
Ras4B possesses no cysteine residues but its interaction with
cellular membranes is favoured by the presence of a polybasic
domain. These differences are critical to determine the traffic and
site of action of Ras proteins (reviewed in [4,7]). Thus, H-Ras is
located mainly at the plasma membrane and in endosomes and
traffics to the plasma membrane through the conventional
secretory pathway. In contrast, K-Ras4B has been reported to
interact with microtubules, although the pathway by which it
reaches the plasma membrane is not well characterized. In the
case of H-Ras, a palmitoylation-depalmitoylation cycle regulates
recycling of the protein between the plasma membrane and the
Golgi. Moreover, palmitate groups are important for determining
the interaction of H-Ras with specific membrane microdomains,
its membrane insertion and orientation and its presence in internal
membranes, which in turn may influence the engagement of
various signaling pathways [8,9].
Cyclopentenone prostaglandins (cyPG) are reactive lipidic
mediators that are generated by dehydration of their parent PG.
PGE-type PG give rise to cyPG of the A-series. The J series of
cyPG arise from dehydration of PGD2 by a sequence of well
characterized steps giving rise to the single enone PGJ2 and to the
dienone PG 15d-PGJ2 and D
12-PGJ2 [10,11]. These prostanoids
are produced in increased amounts in situations associated with
inflammation or oxidative stress and they have been shown to
influence cell proliferation and contribute to the resolution of
inflammation [12]. cyPG contain an a,b-unsaturated carbonyl
group in the cyclopentenone ring. Electrophilic carbons conjugat-
ed with this group can suffer the attack of nucleophiles, such as
sulphur atoms, and form Michael adducts. Through this
mechanism, cyPG may covalently modify proteins, leading to
alteration of protein structure and function [13]. We have
previously shown that several cyPG may bind to Ras proteins,
and that this correlates with Ras activation, as evidenced by an
increase in the levels of Ras in its active conformation, and an
activation of Ras dependent pathways [14]. Interestingly, we
observed that modification and activation of Ras proteins by cyPG
with different structure are site-selective. Single enone PG, like
PGA1 or PGJ2 preferentially bound to C118 in H-Ras, which is
located in the GTP binding site, whereas cyPG with dienone
structure preferentially bound to the C-terminal segment contain-
ing C181 and C184 [15]. Interestingly, this preferential binding
resulted in the selective modification of the different Ras proteins:
while dienone cyPG selectively bound to H-Ras, single enone
cyPG could bind to the three Ras proteins, H-, N- and K-Ras4B,
because all three possess the C118 residue. In light of these data,
we formulated the hypothesis that, dienone cyPG, possessing two
electrophilic carbons, could react simultaneously with two different
cysteine residues. The fact that H-Ras is the only Ras protein
possessing two nearby cysteine residues could constitute the
structural basis for its selective modification by cyPG with dienone
structure. Moreover, this observation raised the possibility that the
C-terminus of H-Ras could be the target for other bifunctional
cysteine reagents. Here we have characterized the modification of
the C-terminal region of H-Ras by cyPG dienones as well as by
other bifunctional cysteine reagents and explored the functional
consequences of this modification. Since palmitoylation is a
reversible modification, our results suggest that the reactive
cysteines present in the H-Ras C-terminus may also be targeted
by various small molecules or biological intermediates with
reactivity towards vicinal thiols, with diverse consequences on
H-Ras localization and function.
Results
cyPG with dienone structure bind simultaneously to
C181 and C184 of H-Ras C-terminus
cyPG dienones, such as 15d-PGJ2 and D
12-PGJ2, can covalently
modify H-Ras by preferentially binding the C-terminal peptide
containing C181 and C184 [15]. Given the bifunctional nature of
these dienones, the possibility exists that they simultaneously bind
to both cysteine residues. To investigate this point we have used a
synthetic peptide corresponding to the tryptic fragment K170-
K185 (m/z 1662.7) from H-Ras C-terminus.
Incubation of K170-K185 with 15d-PGJ2 gave rise to the
appearance of a peak of m/z 1979.80 corresponding to the
addition of one PG molecule (Fig. 1A). Moreover, as previously
noted [14,15], several peaks compatible with the oxidation of the
modified peptide (m/z 1994.9 and 2010.7) were observed.
Reduction and alkylation of the control peptide by subsequent
treatment with DTT and iodoacetamide gave the expected peaks
(m/z 1719.6 and 1776.6) corresponding to the carbamidomethyla-
tion of one and two cysteines, respectively. Addition of 15d-PGJ2
to the K170-K185 peptide was not reversed by DTT. Interest-
ingly, carbamidomethylation of the 15d-PGJ2-modified peptide
upon treatment with iodoacetamide was nearly undetectable,
suggesting that the 15d-PGJ2-modified peptide was basically
devoid of free cysteines. Similar results were obtained when the
H-Ras C-terminal peptide was modified by D12-PGJ2, another
cyPG with dienone structure giving rise to a modified peptide with
m/z 1997.5. These results, summarized in Fig. 1B, contrast with
the behavior of PGJ2, a single enone cyPG, which we have
previously shown to form one- or two-cyPG adducts (m/z 1997.4
and 2331.7, respectively) with the H-Ras C-terminal peptide, thus
showing binding to single cysteine residues [15]. Taken together
these results indicate that modification of K170-K185 by cyPG
dienones may involve intramolecular cross-linking of both C181
and C184. The C-terminal peptide of H-Ras does not show a
defined structure in solution [16], but it adopts a precise
conformation upon interaction with membranes [17]. Cross-
linking between C181 and 184 could impose a more rigid
conformation and potentially alter H-Ras membrane interactions.
A theoretical molecular model illustrating the feasibility of 15d-
PGJ2-induced intramolecular cross-linking of the K170-K185
peptide is shown in Fig. 1C.
The small molecule bifunctional reagent phenylarsine
oxide cross-links C181 and C184 of the H-Ras C-terminal
peptide
In view of the ability of cyPG with dienone structure to
simultaneously bind the cysteine residues of the H-Ras hypervari-
able domain, we tested other small bifunctional molecules for
cross-linking of these two cysteines. The tyrosine phosphatase
inhibitor phenylarsine oxide (PAO, mass 168.02), widely used in
signal transduction studies and as an endocytosis inhibitor [18,19],
is also known to form adducts with proteins by reacting with
vicinal sulfhydryl groups of proteins forming thioarsine rings
[20,21,22]. Incubation of K170-K185 with PAO resulted in the
formation of an adduct of m/z 1812.7 (Fig. 2A), with a mass
increment of 150, compatible with the formation of a cross-link
between C181 and C184 and one PAO molecule, which implies
Intramolecular Cross-Linking of H-Ras C-Terminus
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the loss of the oxygen atom of the PAO molecule plus two
hydrogen atoms (Fig. 2B). Analysis of this 1812.7 peak by MALDI-
TOF-TOF MS/MS gave fragments compatible with the incor-
poration of PAO at the proposed sites (Fig. 2C). The smallest
fragment detected containing the mass increment compatible with
PAO addition corresponded to ion y5 of sequence CMSCK,
confirming the site of modification. Figure 2D depicts a homology
molecular model of the H-Ras C-terminal peptide after cross-
linking elicited by PAO binding.
In contrast with the cross-linking by cyPG with dienone
structure, PAO addition was fully reversible upon treatment with
excess DTT. Thus, PAO-modified K170-K185 underwent
carbamidomethylation at one or two cysteines after incubation
with DTT and iodoacetamide (Fig. 3A, upper panels). Given the
reversibility of PAO addition by competing agents like DTT, we
were interested in exploring whether PAO-induced modification
of the K170-K185 H-Ras peptide would occur in the presence of a
biologically relevant thiol compound at concentrations close to
those encountered in vivo. Interestingly, the presence of
glutathione (GSH) in the incubation mixture reduced the
proportion of PAO-peptide adduct formed in a concentration-
dependent manner, as it can be deduced from the abundance of
modified (m/z 1812.7) vs parent (m/z 1662.7) peptide (Fig. 3A,
lower panels). However, a substantial proportion of PAO-peptide
adduct could still be detected at GSH concentrations of up to
10 mM, thus suggesting that H-Ras modification by PAO could
occur in cells. Remarkably, at 10 mM GSH, peaks of m/z 1967. 7
and 2272.8, compatible with the mono and di-glutathiolation of
K170-K185 were also observed. A summary of the species
encountered in the MS analysis of the K170-K185 peptide adducts
after treatment with the various agents used is shown in Fig. 3B.
PAO binds to H-Ras C-terminus in vitro and in intact cells
In view of the above results we explored whether PAO could
bind to the full length H-Ras protein in vitro, and if so, whether
the peptide containing C181 and C184 was the preferred site for
interaction. As it can be observed in Fig. 4A incubation of full-
length H-Ras with PAO resulted in the formation of an adduct
containing one PAO molecule bound to H-Ras, as clearly detected
by MALDI-TOF MS analysis. Moreover, tryptic digestion of the
modified protein revealed the appearance of a peak with m/z
1812.7 as the main modified peptide, which corresponded to the
addition of one PAO molecule to the K170-K185 tryptic peptide
(Fig. 4B). We have previously reported that biotinylated 15d-PGJ2
(15d-PGJ2-B) binds to H-Ras in vitro and in intact cells at the same
peptide [14,15]. Therefore, we explored the capacity of PAO to
block the binding of 15d-PGJ2-B to H-Ras, by using a gel-based
assay. Pre-incubation with PAO clearly reduced the incorporation
of 15d-PGJ2-B into H-Ras in vitro (Fig. 4C). This could be
evidenced both by the reduction of the H-Ras-associated biotin
signal (28%67 reduction with respect to vehicle-treated Ras,
mean 6 standard deviation of three assays), and by the reduction
Figure 1. Modification of the K170-K185 peptide from the C-terminal region of H-Ras by cyPG. (A) The synthetic K170-K185 peptide was
incubated with the indicated cyPG and the resulting adducts analyzed by MALDI-TOF MS. When indicated, incubation mixtures were treated with
50 mM iodoacetamide after addition of 10 mM DTT. Spectra presented are representative from at least three independent assays per experimental
condition. Structures of the cyPG used are shown in insets. Electrophilic carbons are marked by asterisks. (B) Summary of the theoretical peptide
adducts for which compatible peaks were observed experimentally. +CAM indicates that the peak is compatible with the formation of
carbamidomethyl cysteine subsequent to iodoacetamide treatment. (C) Ribbon diagram for the theoretical backbone structure of the H-Ras K170-
K185 peptide (in green) modified by addition of 15d-PGJ2 to cysteines 181 and 184. The side-chains of the cysteine residues and the 15d-PGJ2 ligand
are displayed in yellow and a default atom-type color scheme, respectively.
doi:10.1371/journal.pone.0015866.g001
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of the amount of 15d-PGJ2-B modified protein, which appears as a
higher molecular weight band (marked by an asterisk), as we have
previously described [15]. We next explored the effect of PAO on
15d-PGJ2-B binding to H-Ras in intact cells by using COS-7 cells
transiently transfected with an expression vector for AU5-tagged
H-Ras. Consistent with previous reports, AU5-H-Ras appeared in
cell lysates as a doublet, reflecting different degrees of posttrans-
lational processing, with the lower band corresponding to the fully
processed H-Ras protein [6]. Incubation with PAO markedly
reduced the extent of modification of H-Ras by 15d-PGJ2-B in
COS-7 cells (Fig. 4D). Quantification of the biotin signal corrected
by AU5-H-Ras protein levels yielded a 55%66 reduction (mean6
standard deviation of three experiments) in 15d-PGJ2-B incorpo-
ration into H-Ras in PAO pre-treated cells. These results indicate
that PAO binds to the C-terminus of H-Ras in intact cells.
Functional consequences of H-Ras modification by PAO
Binding of dienone cyPG or of PAO, as displayed in the
theoretical models, would likely alter the conformational tenden-
cies, and, more importantly, the chemical nature of H-Ras C-
terminus. In addition, since the hypervariable domain cysteine
residues are sites of palmitoylation, incorporation of PAO could
have consequences for the membrane binding or the hydropho-
bicity of the modified protein. Therefore, we explored whether
treatment of cells with PAO led to alterations in H-Ras subcellular
distribution. Treatment of AU5-H-Ras transfected COS-7 cells
with PAO led to a decrease in the amount of membrane associated
H-Ras, as evidenced by cell fractionation into P100 and S100
fractions (Fig. 5A). Partition into the detergent Triton-X114 has
been shown to constitute an assay for protein hydrophobicity [23]
and it has been used as an index of H-Ras lipidation [24]. Indeed,
isoprenylation has been shown to increase the proportion of H-
Ras partitioning into the Triton-X114 phase, this being further
increased by palmitoylation [6]. A Triton X-114 partition assay
showed that treatment of AU5-H-Ras transfected cells with PAO
reduced the amount of H-Ras protein in the detergent phase in a
concentration-dependent manner, mostly at the expense of the
upper component of the AU5-H-Ras doublet, with a concomitant
increase in the protein recovered in the aqueous fraction (Fig. 5B).
Therefore, these results suggest that PAO impairs lipidation of H-
Ras in cells. We were then interested in assessing the effect of PAO
on H-Ras function. Given the reversible nature of PAO binding
we employed a Raf Ras binding domain (Raf-RBD) redistribution
assay, which allows exploring Ras activation in intact cells. The
Figure 2. Modification of the K170-K185 peptide by PAO. (A) The K170-K185 peptide was incubated with PAO and analyzed by MALDI-TOF
MS. Results are representative from at least four assays. (B) Scheme of the formation of a PAO adduct with two thiol groups. (C) Analysis of the PAO-
peptide adduct by MALDI-TOF-TOF MS/MS analysis. The sequence of the peptide with the fragments generated is shown for reference. (D) Ribbon
diagram for the theoretical backbone structure of H-Ras K170-K185 peptide model (in green) modified by PAO addition. The side-chains of the
cysteine residues and PAO are displayed in yellow and a default atom-type color scheme, respectively.
doi:10.1371/journal.pone.0015866.g002
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YFP-RBD construct showed a diffuse distribution in transiently
transfected COS-7 cells. Treatment with EGF led to a more
irregular intracellular YFP-RBD pattern and, above all, to the
appearance of defined accumulations of the fluorescent construct
at the cell periphery, in some cases at the edge of membrane ruffle-
like structures, thus indicating the recruitment of YFP-RBD by
activated Ras at the plasma membrane (Fig. 6A). Incubation with
PAO caused intracellular redistribution of YFP-RBD, resulting in
a more particulate pattern. Interestingly, pre-treatment with PAO
completely blocked EGF-induced recruitment of YFP-RBD to the
plasma membrane. This indicates that Ras activation at the
plasma membrane is blocked by PAO. Quantitation of these
results is shown in Fig. 6B.
We next explored Ras activation by means of a RBD pull-down
assay (Fig. 6C). EGF clearly activated H-Ras in this assay, as
deduced from the increase in the retention of AU5-H-Ras on RBD
beads. No AU5 signal was detected in the pull-down from cells
transfected with empty vector (results not shown). Notably,
treatment with PAO alone induced the retention on RBD beads
of the slower migrating AU5-H-Ras band and did not reduce
EGF-induced Ras activation in this assay. Taken together these
results suggest that PAO treatment targets H-Ras in intact cells
and alters H-Ras-mediated signaling by selectively blocking EGF-
mediated Ras activation at the cell membrane and potentially
inducing Ras-Raf interaction at other locations.
The cysteine cross-linking agent dibromobimane targets
H-Ras hypervariable domain
The results shown above suggest that small molecules
interacting with spatially vicinal cysteines may induce an
intramolecular cross-linking of H-Ras hypervariable domain and
alter Ras distribution and signaling. To further substantiate this
point, we studied the effect of dibromobimane (DBB, mass
350.01), a reagent known to cross-link cysteine residues within 3–
6 A˚ distance [25]. DBB was shown to bind K170-K185 by MS
analysis (Fig. 7A). The m/z of the modified peptide (1850.81) was
compatible with addition of one DBB molecule to C181 and
C184, according to the reaction depicted in Fig. 7B (expected mass
increment 188.0). Formation of peptide dimers was not detected,
again suggesting the occurrence of intramolecular cysteine cross-
linking by DBB. Moreover, reduction and alkylation with
iodoacetamide did not result in carbamidomethylation of the
DBB-modified peptide, thus ruling out the presence of free
cysteines. As observed for PAO, treatment of full length H-Ras
with DBB reduced the modification of the protein by 15d-PGJ2-B,
suggesting that DBB binds to H-Ras at the C-terminal peptide
Figure 3. Effect of reducing agents on PAO modification of the K170-K185 peptide. (A) In the upper panels, the K170-K185 peptide was
incubated with PAO and analyzed by MALDI-TOF MS. In the right panel, the incubation mixture was treated with 10 mM DTT and subsequently with
50 mM iodoacetamide. In the lower panels, the K170-K185 peptide was incubated with PAO in the presence of the indicated concentrations of GSH
before analysis by MALDI-TOF MS. (B) Summary of the theoretical m/z of peptides for which compatible peaks were observed experimentally in the
assays shown in (A).
doi:10.1371/journal.pone.0015866.g003
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(Fig. 7C). Indeed, direct binding of DBB to H-Ras could be
evidenced by fluorescence detection of the gels, taking advantage
of the fluorogenic properties of this compound upon replacement
of both bromines [25] (Fig. 7C). Although DBB has been widely
used in cysteine mapping studies in vitro, its effects in cultured cells
have not been explored. Therefore, at this point we went on to
assess whether DBB recapitulated some of the effects of PAO in
intact cells. A concentration of 50 mM DBB was required to detect
binding of this compound to intracellular components, as observed
by confocal fluorescence microscopy (results not shown). This
concentration did not affect cell viability nor elicited morpholog-
ical changes. Under these conditions, treatment of AU5-H-Ras-
transfected cells with DBB reduced the levels of the upper
component of AU5-H-Ras doublet (Fig. 7D) and led to the virtual
disappearance of this band from the detergent phase in the Triton
X-114 partition assay (Fig. 7E). Finally, using the Raf-RBD
redistribution assay, we observed that in the presence of DBB,
YFP-RBD adopted a particulate intracellular pattern and EGF
failed to induce the translocation the YFP-RBD construct to the
cell periphery or to membrane ruffle-like structures (Fig. 7F).
Therefore, DBB markedly alters H-Ras homeostasis and function.
Discussion
Ras proteins are critical signaling molecules that integrate
information from growth factor receptors and intracellular
mediators. Ras proteins may sense changes in calcium concentra-
tion or redox state and engage various signaling pathways leading
to the regulation of basic cellular functions. The ability of Ras
proteins to act as sensors of various stimuli in different cell
compartments relies in part in the complex array of posttransla-
tional modifications they can undergo. Ras proteins may be
subjected to isoprenylation and accompanying modifications,
proteolysis and carboxyl methylation, phosphorylation, palmitoy-
lation, ubiquitination and various non-enzymatic modifications
including nitrosylation, thiolation or addition of lipid electrophiles
[14,26,27,28]. Here we show that the C-terminal end of H-Ras
proteins may be the target for both endogenous reactive molecules
Figure 4. PAO binds to the C-terminal peptide of H-Ras in vitro and in cells. (A) Full length H-Ras was incubated with PAO and analyzed by
MALDI-TOF MS. (B) Control or PAO-treated H-Ras was subjected to tryptic digestion and the resulting peptides analyzed by MALDI-TOF MS. The peak
of m/z 1812.27, corresponding to the formation of an adduct between PAO and the K170-K185 peptide, is marked by an asterisk. Dotted lines mark
the positions equivalent to those of the modified species in the untreated samples. (C) H-Ras at 5 mM was incubated with 50 mM PAO for 30 min
before addition of 1 mM biotinylated 15d-PGJ2 (15d-PGJ2-B) for 1 h. (D) COS-7 cells were transiently transfected with empty vector or a plasmid
coding for AU5-H-Ras. 24 h after transfection cells were pre-treated with vehicle or 1 mM PAO for 90 min before incubation with 5 mM 15d-PGJ2-B for
90 min. Incubation mixtures from (C) and cell lysates from (D) were analysed by SDS-PAGE followed by transfer to membrane and detection of
incorporated biotin with horseradish peroxidase (HRP)-streptavidin and of the Ras protein by immunoblot with anti-pan Ras or anti-AU5 antibody
and enhanced chemiluminescence (ECL). Results shown are representative of at least three assays.
doi:10.1371/journal.pone.0015866.g004
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and exogenous chemicals that cross-link nearby cysteines, thus
opening new possibilities for the regulation of Ras proteins and
potentially for H-Ras-selective signaling.
In this and previous works we have reported that Ras proteins
are targets for modification by endogenous electrophilic eicosa-
noids, like cyPG and isoprostanes [14,15]. From a structural point
of view, different patterns of modification by eicosanoids with
different structure were encountered, with single enone com-
pounds preferentially modifying C118, which is present in all three
Ras proteins, and dienone compounds, like 15d-PGJ2, binding
preferentially to the C-terminal peptide containing C181 and 184,
present only in H-Ras. Analogously to the selective modification
and activation of H-Ras, but not N-Ras or K-Ras4B, by 15d-PGJ2
[15], we have observed that PAO, shown here to modify H-Ras,
did not affect the electrophoretical mobility or activation of AU5-
K-Ras4B (results not shown). This suggests that the presence of
two close cysteine residues in the hypervariable domain of H-Ras
may be the main determinant for its selective modification by
cyPG dienones, and possibly by other bifunctional cysteine
reagents.
In this context, various recent evidences suggest that cyPG
dienones could preferentially modify proteins containing cysteines
in close proximity. Given the stability of this modification, this
could result in intra- or inter-molecular cross-linking. Indeed, we
have recently reported that dienone cyPG, like 15d-PGJ2 and D
12-
PGJ2 induce cross-linking of the P1-1 isoform of glutathione S-
transferase (GST), which is involved in cancer chemoresistance,
through a mechanism likely involving cysteine residues present in
different GSTP1-1 monomers [29]. Moreover, 15d-PGJ2 has also
been shown to directly cross-link c-Jun monomers in vitro [30]. In
view of these findings it would be interesting to explore whether
proteins with neighboring cysteines important for function, such as
thioredoxins, tyrosine phosphatases, Rho proteins or Hsp90
constitute preferential targets for cyPG with dienone structure
[20,31,32].
It should be taken into account that the cysteine residues of H-
Ras targeted by the agents used in this study are the palmitoylation
cysteines located in the hypervariable domain. Since H-Ras
palmitoylation plays a key role in subcellular localization [8],
modification of these cysteine residues could be expected to alter H-
Ras distribution. We previously observed that treatment of cells with
15d-PGJ2 did not disrupt membrane association of H-Ras, although
an increased extractability in detergent was noted, indicative of
potential changes in H-Ras membrane microdomain distribution
[15]. The results presented here indicate that C181 and C184 of H-
Ras can be targeted by several bifunctional molecules of diverse
structure, such as PAO and DBB. Our results indicate that H-Ras
modification by these agents takes place in vitro and in cells.
Moreover, treatment with PAO decreases H-Ras hydrophobicity
and membrane binding. In turn, the most obvious effect of DBB
under the conditions studied is a reduction in the levels of the upper
component of the H-Ras doublet, putatively the non-palmitoylated
form, causing its disappearance from the detergent fraction. A
reduction in the levels of the slower migrating form of H-Ras was
also observed with high (10 mM) PAO concentrations (results not
shown). Whether the decrease in the detection of the upper H-Ras
band is due to protein aggregation, degradation or other
mechanisms, it will be the subject of further studies.
Palmitoylation is a reversible modification, with a half-life that
has been measured as approximately 20 min compared to the
20 h half-life of the protein [33]. In addition, Ras depalmitoylation
can be stimulated by Ras activation [4], whereas S-nitrosocysteine
treatment has been reported to modulate palmitate turnover by
stimulating H-Ras deacylation and allowing subsequent reacyla-
tion [34]. It is possible therefore, that during the palmitoylation-
depalmitoylation cycle of H-Ras, C181 and C184 may become
Figure 5. Effect of PAO on H-Ras subcellular localization. (A) COS-7 cells were transiently transfected with expression vectors coding for AU5-
H-Ras wt. After serum starvation for 16 h, cells were treated with vehicle or 1 mM PAO for 1 h. Cells were lysed and postnuclear supernatants were
separated into S100 and P100 fractions by ultracentrifugation at 200,0006 g for 30 min. (B) AU5-H-Ras transfected cells were treated with the
indicated concentrations of PAO for 90 min and cell lysates were subjected to fractionation in Triton-X114. The amount of AU5-H-Ras present in the
various fractions was estimated by western blot with anti-AU5 antibody (upper panels). The upper component of the H-Ras doublet is indicated by an
arrowhead. Levels of actin were assessed as control (lower panels). Blots shown are representative of three assays.
doi:10.1371/journal.pone.0015866.g005
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available for chemical modification by various agents or by
oxidation. Depending on its stability, this modification could
interfere with subsequent palmitoylation and palmitoylation-
dependent subcellular localization or microdomain partitioning
of H-Ras. According to the current knowledge, depalmitoylation
of H-Ras would occur subsequently to activation and allow
recycling of the protein towards the Golgi complex, where it would
be re-palmitoylated. Indeed, non-palmitoylatable versions of H-
Ras have been found to localize primarily on the Golgi and signal
mainly from this platform in response to growth factor stimulation
[8]. In addition, active H-Ras has been detected at the
endoplasmic reticulum and on recycling endosomes in route
towards the plasma membrane [35]. Interestingly, mutation of
C184 for a more hydrophobic leucine residue has been proposed
to be able to substitute for the presence of palmitate at this position
and support binding of H-Ras to plasma membrane and recycling
endosomes [35]. In light of our data, it would be tempting to
hypothesize that the modification of C181 and C184 of H-Ras
through the addition of electrophilic endogenous mediators or
chemical agents could differentially affect the site of action of this
GTPase depending on the structure and/or hydrophobicity of the
bound molecule.
We have previously shown that modification of Ras proteins by
various eicosanoids, including 15d-PGJ2, PGA1 [15], D
12-PGJ2 or
8-iso-PGA1 (Oeste et al., unpublished results), correlates with
activation of Ras-dependent pathways, although the precise site of
H-Ras activation by these various eicosanoids needs to be studied
in detail. Here we have observed that PAO induces an increase in
H-Ras binding to RBD. Moreover, the observations that both
PAO and DBB induce a cytosolic particulate pattern of YFP-RBD
in cells could be indicative of the activation of Ras proteins in
endomembranes. Although further work is needed to establish this
point, our results with PAO selectively blocking redistribution of
YFP-RBD towards the plasma membrane (live cell assay), but not
the total RBD binding capacity of H-Ras after EGF stimulation
(pull-down assay) would support this hypothesis. Moreover, we
observed retention of the slower migrating form of H-Ras on RBD
beads upon treatment with PAO. Whether this band represents
PAO-modified protein and its precise subcellular localization will
be the subject of future studies.
In this work we have used various electrophilic agents as tools to
target the palmitoylation cysteines of H-Ras. However, it should
be kept in mind that the compounds used may bind to multiple
cellular targets. Moreover, thiol-reactive compounds may alter the
Figure 6. Effect of PAO on Ras activation. (A) COS-7 cells were transfected with YFP-RBD, serum starved for 16 h and pre-incubated with vehicle
or 1 mM PAO for 1 h before stimulation with 100 nM EGF. Cells were visualized live by confocal fluorescence microscopy. Shown are representative
images from at least five experiments with similar results. Dotted inserts show enlarged areas from the same cells for better visualization. Arrowheads
mark the accumulation of YFP-RBD at defined locations of the cell periphery. Bar, 20 mm. At least 40 cells were monitored per experimental condition
and the percentage of cells showing accumulations of YFP-RBD at the cell periphery is shown in (B) as average values6 standard error of mean (SEM)
of five independent experiments. (C) Cells were treated as above and cell lysates were subjected to pull-down on GST-RBD beads for collection of Ras
in its active conformation. Levels of RBD-bound and total AU5-H-Ras were assessed by western blot. Results shown are representative of three assays.
The lower panel presents the quantitation of RBD-bound AU5-H-Ras/total AU5-H-Ras ratios from three independent experiments as average values6
SEM. *p,0.05 vs vehicle.
doi:10.1371/journal.pone.0015866.g006
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cellular redox state and have an impact on the oxidative
modifications of proteins [21,36]. In particular, PAO, widely used
as a tyrosine phosphatase inhibitor in cells, may interfere with
numerous signaling pathways [20,21]. Indeed, interaction of PAO
with Ras signaling pathways has been reported to lead to diverse
effects, in some cases of complex interpretation. PAO has been
reported to block Ras activation by insulin in murine fibroblasts
[37], but not to reduce EGF-induced Ras activation in HEK-293
cells [38]. Our results showing that H-Ras proteins can be direct
targets for modification by this compound add further complexity
to this picture and call attention to the need of interpreting these
results cautiously.
In summary, our results show that bifunctional cysteine reagents
can target the hypervariable region of H-Ras and that this
interaction may have multifaceted consequences for Ras distribu-
tion and signaling.
Materials and Methods
Materials
The prostanoids used throughout this study were from Cayman
Chemical (Ann Arbor, MI). Human recombinant H-Ras was from
Calbiochem-Novabiochem (San Diego, CA). Anti-AU5 monoclo-
nal antibody was from Berkeley Antibody Company (Berkeley,
CA), anti-pan Ras (Ab-3) was from Merck. Phenylarsine oxide
(PAO), dibromobimane (DBB) and epidermal growth factor (EGF)
were purchased from Sigma-Aldrich (St. Louis, MO). Raf-Ras
binding domain (Raf-RBD) protein agarose beads were from
Cytoskeleton, Inc.
Synthesis of H-Ras C-terminal peptide
Peptide KLNPPDESGPGCMSCK, corresponding to amino
acids K170 to K185 of human H-Ras, henceforth referred to as
Figure 7. Interaction of the bifunctional reagent DBB with H-Ras. (A) Modification of the K170-K185 peptide by DBB. The K170-K185 peptide
was incubated with DBB, as described in the Methods section. When indicated the incubation mixture was subjected to reduction and alkylation with
iodoacetamide to modify free cysteines. Results are representative of three independent assays. (B) Scheme of the cross-linking of two thiol groups
by DBB. (C) Competition of 15d-PGJ2-B binding to H-Ras by DBB. H-Ras at 5 mM was incubated with 50 mM DBB for 30 min before addition of 1 mM
15d-PGJ2-B for 1 h. Incorporation of the biotinylated PG was assessed by SDS-PAGE, protein blot and detection with horseradish peroxidase (HRP)-
streptavidin (upper panel). Incorporation of DBB (middle panel) and total H-Ras levels (lower panel) were assessed by fluorescence detection and
western blot with anti-pan Ras antibody, respectively. (D) COS-7 cells transfected with the AU5-H-Ras vector were treated in the absence or presence
of 50 mM DBB for 1 h. Aliquots from total cell lysates (10 mg of protein) were analyzed by SDS-PAGE. The upper component of the AU5-H-Ras doublet
is indicated by an arrowhead. (E) COS-7 cells transfected with the AU5-H-Ras vector were treated with DBB and subjected to fractionation in Triton-
X114 as above. In (D) and (E) levels of AU5-H-Ras were assessed by western blot with anti-AU5 antibody. The dotted line marks where lanes from the
same gel have been cropped. (F) COS-7 cells transfected with YFP-RBD as above were treated with 50 mM DBB for 1 h before stimulation with 100 nM
EGF, as indicated, and visualized live by confocal fluorescence microscopy. Dotted inserts show enlarged areas from the same cells for better
visualization. Arrowheads mark the accumulation of YFP-RBD at defined locations of the cell periphery. Bar, 20 mm. Shown are representative images
from three experiments with similar results.
doi:10.1371/journal.pone.0015866.g007
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K170-K185, was chosen as a model because it is the major
modified peptide detected after tryptic digestion of 15d-PGJ2- and
D12-PGJ2-treated H-Ras [15]. The peptide was produced by solid
phase methods [39] in an ABI 433A synthesizer (Applied
Biosystems, Foster City, CA), using Fmoc (9-fluorenylmethoxy
carbonyl) chemistry and 0.1-mmol-scale FastMoc protocols. After
chain assembly, it was cleaved from the resin by acidolysis
with trifluoroacetic acid/water/ethanedithiol/triisopropylsilane
(94:2.5:2.5:1 v/v, 90 min, 25uC), precipitated with chilled methyl
tert-butyl ether, redissolved in 10% (v/v) acetic acid and
lyophilized. Purification by preparative HPLC (Phenomenex C18
column, 21.26250 mm, 10 mm particle size, linear gradient of
solvent B into A –solvent A, 0.045% TFA in H2O; solvent B,
0.036% in acetonitrile– over 35 min, 25 ml/min flow rate) yielded
fractions containing the target dithiol peptide in highly pure form,
with a mass of 1662.73 by MALDI-TOF mass spectrometry.
Plasmids and transfections
The plasmids pCEFL-KZ-AU5 and pCEFL-KZ-AU5-H-Ras
wt have been previously described [14]. An expression plasmid
containing the Ras-binding domain of cRaf (RBD) fused to the
Yellow Fluorescent Protein (pEYFP-RBD) was prepared from a
RBD-pECFP plasmid generously donated by Dr. MR Philips.
COS-7 cells were grown in DMEM supplemented with 10% fetal
bovine serum, 2 mM glutamine, 100 U/ml penicillin and 100 mg/
ml streptomycin. Transient transfections were performed using
Lipofectamine 2000 (Invitrogen), according to the instructions of
the manufacturer. Treatments with the various agents used were
performed in the absence of serum. Prostanoids and PAO were
added in DMSO (vehicle) and control cells received an equivalent
amount of vehicle.
Analysis of the interaction between H-Ras and small
molecules in vitro
H-Ras or K170-K185 Ras peptide were incubated at 5 mM in
the presence of prostanoids, DBB or PAO at 50 mM or vehicle
(DMSO), as previously described [15]. For some experiments, H-
Ras incubation mixtures were then subjected to digestion with
trypsin for 4 h at 37uC. When indicated, aliquots of H-Ras, tryptic
digests or K170-K185 peptide were subsequently incubated with
10 mM DTT for 30 min followed by 50 mM iodoacetamide for
30 min at r.t. before purification on ZipTip C18 (Millipore) and
MALDI-TOF MS analysis on an AUTOFLEX III MALDI-TOF-
TOF instrument (Bruker-Franzen Analytik, Bremen, FRG)
operated in the positive mode, as reported in detail [15]. Selected
peptides were further analyzed by MALDI-TOF-TOF MS/MS.
Interaction of 15d-PGJ2-B and recombinant H-Ras was also
explored by SDS-PAGE, protein transfer to Immobilon-P
membranes and detection of incorporated biotin with horseradish
peroxidase (HRP)-Streptavidin and enhanced chemiluminescence
(ECL), as previously described [14]. Direct binding of DBB to H-
Ras was assessed by visualization of the gel under UV light on a
Gel-Doc XR Imaging System (Bio-Rad), as described [25].
Unreacted DBB, which is essentially non-fluorescent, becomes
fluorescent upon cross-linking (excitation maximum 385 nm,
emission, 477 nm).
Molecular-building procedure
Structural studies on H-Ras indicate that the C-terminal
segment lacks a defined structure in solution [16]. Therefore, we
used a molecular-building approach for modelling this peptide.
The recognition of an overall fold for the H-Ras K170-K185
peptide was based on the threading prediction from the
THREADER program [40]. A three-dimensional model for the
sequence of the K170-K185 peptide was built using a knowledge-
based protein modelling method based on the given pair-wise
target-template sequence alignment to the 156-171 spanning
region of the 2.4 A˚ resolution X-ray structure of a CRISP family
Ca2+-blocker (PDB code 1wvr) as template. This particular
template was chosen on the basis of its high sequence identity
with the Ras C-terminal peptide (sequence alignment shows a 44%
sequence identity with a ratio of aligned/gap positions of 16/0 as
yielded by a global alignment algorithm), its low-density map of
inter-residues interactions and a relatively high relation of surface/
buried residues. Nevertheless, it should be taken into account that
the structure obtained is a theoretical homology model, which
serves the purpose, not of defining a structure for the K170-K185
H-Ras peptide, but of illustrating the feasibility of the modifica-
tions described. The 3D-configurations of 15d-PGJ2 and PAO
ligands were obtained from the PubChem database (http://
pubchem.ncbi.nlm.nih.gov, CID codes 5280885 and 4778,
respectively). Computational resources from the SWISS-MODEL
homology modeling server [41] were used to achieve the final
structural model for the K170-K185 peptide. The structure
alignment of the 156–171 spanning region of 1wvr with the K170-
K185 peptide model shows a likely identical fold, with a backbone-
atoms root-mean-square deviation of 0.12 A˚. The stereochemical
quality of that model and its structural self-consistency were
assessed with PROCHECK [42] and Verify-3D [43] programs,
respectively. The initial molecular conformations for the adducts
were subjected to a constrained energy minimization step in order
to remove steric clashes. Computations were performed with the
MacroModel 9.5 software (Schro¨dinger Suite 2007 Update 2,
2007). Final figures were carried out with the Swiss-Pdb Viewer
v4.0 program (http://www.expasy.org/spdbv/).
Binding of 15d-PGJ2-B to Ras proteins in intact cells
COS-7 cells transiently transfected with Ras plasmids were
incubated with 15d-PGJ2-B for 2 h. Cells were lysed in 50 mM
Tris-HCl, pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.1 mM 2-
mercaptoethanol, 0.5% SDS containing protease inhibitors (2 mg/
ml each of leupeptin, aprotinin and pepstatin, and 1.3 mM
ABMSF), and incorporation of 15d-PGJ2-B into Ras proteins was
assessed by western blot with HRP-streptavidin, essentially as
described [14].
Analysis of H-Ras localization and activation
The effect of PAO on H-Ras subcellular localization was
assessed by obtaining S100 and P100 fractions, as described [44].
H-Ras hydrophobicity was assessed by partition in Triton X-114,
as previously described [45]. Briefly, COS-7 cells transfected with
AU5-H-Ras and treated with the indicated agents were lysed in
20 mM Tris HCl, pH 7.5, 150 mM MaCl, 1% Triton X-114,
containing protease inhibitors as above, for 1 h at 4uC with
occasional shaking. After 3 min incubation at 37uC lysates were
centrifuged at 12000 rpm for 3 min for phase separation. Aqueous
phase was collected and the detergent phase was re-extracted with
lysis buffer without Triton X-114. The second aqueous phase was
discarded and the detergent phase was resuspended in a volume of
buffer, without detergent, equal to the starting volume of lysate
used for fractionation. Equal volumes of aqueous and detergent
phases were analyzed by SDS-PAGE and western blot.
H-Ras activation in intact cells was monitored by two
complementary assays. For a Ras activation-redistribution assay,
COS-7 cells cultured on glass bottom dishes from Mattek Corp.
(Ashland, MA) were transiently transfected with YFP-RBD and
serum starved for 16 h, after which they were stimulated with the
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indicated compounds. The distribution of YFP-RBD was observed
by confocal fluorescence microscopy in live cells using a Leica
DMRE2 microscope (LEICA, Heidelberg, Germany). In this
assay, YFP-RBD shows a diffuse distribution in non-stimulated
cells, whereas Ras activation recruits YFP-RBD causing its
accumulation in defined areas [8]. For quantitation, the
proportion of cells showing plasma membrane-associated YFP-
RBD was assessed. All experiments were repeated at least three
times and representative results are shown. For a Raf RBD pull-
down assay, cells were lysed in 25 mM Hepes, pH 7.5, 150 mM
NaCl, 10% glycerol, 10 mM MgCl2, 1% NP-40, 1 mM EDTA,
0.25% deoxycholic acid containing 25 mM FNa, 1 mM sodium
orthovanadate, 10 mg/ml leupeptin and aprotinin and 1.3 mM
ABMSF. Cell lysates were incubated with Raf-RBD agarose beads
with rotary shaking for 1 h at 4uC. After extensive washing, bound
proteins were eluted by incubation for 5 min at 95uC in Laemmli
sample buffer. The amount of AU5-H-Ras retained on Raf-RBD
beads and that present in total cell lysates used for pull-down was
assessed by western blot.
Statistical analysis
The data shown are the mean 6 SE of at least three
experiments. Statistical significance was estimated with the
Student’s t test for unpaired observations. A p value of less than
0.05 was considered significant.
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